MELBOURNE, Australia, Dec. 17 /PRNewswire-FirstCall/ --
Treatment for Diabetic Patients a Major New Objective
*Single injection of proprietary adult stem cells resulted in increased blood insulin levels and sustained reduction in blood glucose levels
*Stem cell treatment induced two-fold increase in total numbers of pancreatic islets, and increase in insulin-producing beta cells
*Results indicate pancreas may successfully be regenerated by proprietary adult stem cells
*Estimated 230 million people worldwide suffer from diabetes; massive commercial opportunity
*Plans to commence clinical trial program
Australia's regenerative medicine company, Mesoblast Limited (ASX: MSB), today announced significant preclinical trial results showing that the proprietary adult stem cell platform could be an effective treatment for diabetes.
In the study, led by Dr. Ravi Krishnan, Senior Scientist at the Queen Elizabeth Hospital in Adelaide, South Australia, in collaboration with Mesoblast's United States-based associate company Angioblast Systems Inc., a single dose of the patented human Mesenchymal Precursor Cells (MPCs) injected into mice with diabetes resulted in a significant increase in blood insulin levels and sustained reduction in blood glucose levels for the entire three week period of follow-up. This was due to restoration in the damaged pancreas of the balance between insulin-producing beta cells, which reduce blood glucose, and glucagon-producing alpha cells, which increase blood glucose.
Leading international diabetes expert Professor Michael Horowitz, Director of the Endocrine and Metabolic Unit at the Royal Adelaide Hospital, who has reviewed the results said: "These data are very exciting, and clearly demonstrate the potential of using these unique adult stem cells in the treatment of patients with Type 2 diabetes."
Copyright©2009 PR Newswire.
All rights reserved